Will BioNTech and MediLink terminate the cancer drug trial by end of 2024? | Binary | | | 6 months ago | |
What will be the outcome of BioNTech's cancer drug trial by end of 2024? | Categorical | | | 6 months ago | |
Next milestone for Ivonescimab by end of 2024? | Categorical | | | 7 months ago | |
Summit Therapeutics stock price above $10 by August 31, 2024? | Binary | | | 7 months ago | |
Ivonescimab FDA approval for NSCLC by end of 2024? | Binary | | | 7 months ago | |
Company with highest stock increase in 2024 following Ivonescimab news? | Categorical | | | 7 months ago | |
Global mRNA vaccine development trends post-Moderna patent win | Categorical | | | 7 months ago | |
Impact on COVID-19 vaccine market share post-Moderna patent victory | Categorical | | | 7 months ago | |
Will Moderna pursue further legal action against Pfizer and BioNTech in 2024? | Binary | | | 7 months ago | |
New mRNA technology partnerships formed post-patent ruling | Categorical | | | 7 months ago | |
Moderna stock rise over 10% post-patent decision? | Binary | | | 7 months ago | |
Moderna secures another COVID-19 vaccine patent in 2024? | Binary | | | 7 months ago | |
Best performing stock post-patent decision: Moderna, Pfizer, or BioNTech? | Categorical | | | 7 months ago | |
Who will lead COVID-19 vaccine market share by 2024 end? | Categorical | | | 7 months ago | |
Will BioNTech's mRNA lung cancer vaccine BNT116 be approved for use in the EU by August 31, 2025? | Binary | | | 4 months ago | |
Will there be further fatalities in BioNTech's cancer drug trial by end of 2024? | Binary | | | 6 months ago | |
Will the FDA lift the partial hold on BioNTech's cancer drug trial by end of 2024? | Binary | | | 6 months ago | |
Merck files legal challenge against Summit Therapeutics by end of 2024? | Binary | | | 7 months ago | |
Peak market cap of Summit Therapeutics in 2024? | Categorical | | | 7 months ago | |
Most trusted vaccine company post-patent dispute: Moderna, Pfizer, or BioNTech? | Categorical | | | 7 months ago | |
Will Pfizer appeal the COVID patent ruling? | Binary | | | 7 months ago | |
Will BioNTech's mRNA lung cancer vaccine BNT116 receive FDA approval by August 31, 2025? | Binary | | | 4 months ago | |
What will be the impact of BioNTech's mRNA lung cancer vaccine BNT116 on BioNTech's stock price by December 31, 2024? | Categorical | | | 4 months ago | |
Will BioNTech's mRNA lung cancer vaccine receive emergency use authorization in any trial country by March 31, 2025? | Binary | | | 4 months ago | |
Will Pfizer or BioNTech publicly address the batch-dependent safety signal issue by end of 2024? | Binary | | | 4 months ago | |
Will an official report confirm the batch-dependent safety signal in BNT162b2 vaccine by end of 2024? | Binary | | | 4 months ago | |
Will BioNTech's stock price recover to pre-decline levels by September 30, 2024? | Binary | | | 4 months ago | |
Will Pfizer and BioNTech announce a new trial for the COVID-19-Flu vaccine by the end of 2024? | Binary | | | 4 months ago | |
What will be BioNTech's stock price at the end of Q4 2024? | Categorical | | | 4 months ago | |
Will Pfizer and BioNTech's COVID-19-Flu vaccine receive FDA approval for individuals aged 18-64 by the end of 2024? | Binary | | | 4 months ago | |
Will BioNTech secure FDA approval for a new non-COVID-19 product by June 30, 2025? | Binary | | | 5 months ago | |
Will BioNTech's stock price recover to its pre-Q2 earnings report level by December 31, 2024? | Binary | | | 5 months ago | |
Will BioNTech's Q3 2024 earnings report meet or exceed analyst expectations? | Binary | | | 5 months ago | |
What will be the outcome for current patients in BioNTech's cancer drug trial by end of 2024? | Categorical | | | 6 months ago | |
Will Pfizer and BioNTech appeal the European Patent Office decision in 2024? | Binary | | | 7 months ago | |
Will Pfizer and BioNTech's stock prices fall by more than 10% within 3 months of the patent ruling? | Binary | | | 7 months ago | |
Will BioNTech's mRNA lung cancer vaccine BNT116 show statistically significant improvement in survival rates by December 31, 2024? | Binary | | | 4 months ago | |
What will be the outcome of BioNTech's mRNA lung cancer vaccine BNT116 clinical trial by December 31, 2024? | Categorical | | | 4 months ago | |
How many countries will approve BioNTech's mRNA lung cancer vaccine BNT116 by August 31, 2025? | Categorical | | | 4 months ago | |
Which age group will show the most significant response to BioNTech's mRNA lung cancer vaccine in the UK trial by end of 2024? | Categorical | | | 4 months ago | |
Will the 67-year-old patient in the UK trial experience complete remission of lung cancer by August 23, 2025? | Binary | | | 4 months ago | |
Which country will first approve BioNTech's mRNA lung cancer vaccine for general use by December 31, 2025? | Categorical | | | 4 months ago | |
What will be the primary outcome of the UK trial for BioNTech's mRNA lung cancer vaccine by end of 2024? | Categorical | | | 4 months ago | |
Will BioNTech's mRNA lung cancer vaccine show significant survival improvement in UK trial by end of 2024? | Binary | | | 4 months ago | |
What will be the next phase announced for BioNTech's BNT326/YL202 trial by end of 2024? | Categorical | | | 4 months ago | |
Will BioNTech and MediLink successfully complete Phase 1 trial of BNT326/YL202 by end of 2024? | Binary | | | 4 months ago | |
Will BioNTech and MediLink report positive results from Phase 1 trial of BNT326/YL202 by end of 2024? | Binary | | | 4 months ago | |
Will the FDA place another hold on BioNTech's BNT326/YL202 trial by end of 2024? | Binary | | | 4 months ago | |
What will be the outcome of BioNTech and MediLink's Phase 1 trial of BNT326/YL202 by end of 2024? | Categorical | | | 4 months ago | |
What milestone will BioNTech's BNT326/YL202 trial reach by end of 2024? | Categorical | | | 4 months ago | |
Will new guidelines or regulations regarding BNT162b2 vaccine batches be implemented by end of 2024? | Binary | | | 4 months ago | |
What will be the outcome of further investigations into the batch-dependent safety signal of BNT162b2 vaccine by end of 2024? | Categorical | | | 4 months ago | |
What actions will Pfizer and BioNTech take in response to the batch-dependent safety signal findings by end of 2024? | Categorical | | | 4 months ago | |
What will be the outcome of Pfizer and BioNTech's next trial for the COVID-19-Flu vaccine by the end of 2024? | Categorical | | | 4 months ago | |
When will Pfizer and BioNTech's COVID-19-Flu vaccine be launched in the market? | Categorical | | | 4 months ago | |
What will be the primary source of BioNTech's revenue in the Q4 2024 earnings report? | Categorical | | | 5 months ago | |
How will BioNTech distribute its R&D expenditure in Q4 2024? | Categorical | | | 5 months ago | |
How will BioNTech's stock price move following the Q3 2024 earnings report? | Categorical | | | 5 months ago | |
What will be the regulatory action on BioNTech's cancer drug trial by end of 2024? | Categorical | | | 6 months ago | |
What will be the public perception of the BNT162b2 vaccine following the investigation by end of 2024? | Categorical | | | 4 months ago | |
